Cargando…

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

In recent years, new direct-acting antivirals for hepatitis C virus (HCV) have been approved, but hepatitis C continues to pose a threat to human health. It is important to develop neutralizing anti-HCV antibodies to prevent medical and accidental infection, such as might occur via liver transplanta...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokokawa, Hiroshi, Shinohara, Midori, Teraoka, Yuji, Imamura, Michio, Nakamura, Noriko, Watanabe, Noriyuki, Date, Tomoko, Aizaki, Hideki, Iwamura, Tomokatsu, Narumi, Hideki, Chayama, Kazuaki, Wakita, Takaji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499215/
https://www.ncbi.nlm.nih.gov/pubmed/36137152
http://dx.doi.org/10.1371/journal.pone.0274283
_version_ 1784794941770170368
author Yokokawa, Hiroshi
Shinohara, Midori
Teraoka, Yuji
Imamura, Michio
Nakamura, Noriko
Watanabe, Noriyuki
Date, Tomoko
Aizaki, Hideki
Iwamura, Tomokatsu
Narumi, Hideki
Chayama, Kazuaki
Wakita, Takaji
author_facet Yokokawa, Hiroshi
Shinohara, Midori
Teraoka, Yuji
Imamura, Michio
Nakamura, Noriko
Watanabe, Noriyuki
Date, Tomoko
Aizaki, Hideki
Iwamura, Tomokatsu
Narumi, Hideki
Chayama, Kazuaki
Wakita, Takaji
author_sort Yokokawa, Hiroshi
collection PubMed
description In recent years, new direct-acting antivirals for hepatitis C virus (HCV) have been approved, but hepatitis C continues to pose a threat to human health. It is important to develop neutralizing anti-HCV antibodies to prevent medical and accidental infection, such as might occur via liver transplantation of chronic HCV patients and needle-stick accidents in the clinic. In this study, we sought to obtain anti-HCV antibodies using phage display screening. Phages displaying human hepatocellular carcinoma patient-derived antibodies were screened by 4 rounds of biopanning with genotype-1b and -2a HCV envelope E2 protein adsorbed to magnetic beads. The three antibodies obtained from this screen had reactivity against E2 proteins derived from both genotype-1b and -2a strains. However, in epitope analysis, these antibodies did not recognize linear peptides from an overlapping E2 epitope peptide library, and did not bind to denatured E2 protein. In addition, these antibodies showed cross-genotypic neutralizing activity against genotype-1a, -1b, -2a, and -3a cell culture-generated infectious HCV particles (HCVcc). Moreover, emergence of viral escape mutants was not observed after repeated rounds of passaging of HCV-infected cells in the presence of one such antibody, e2d066. Furthermore, injection of the e2d066 antibody into human hepatocyte-transplanted immunodeficient mice inhibited infection by J6/JFH-1 HCVcc. In conclusion, we identified conformational epitope-recognizing, cross-genotypic neutralizing antibodies using phage display screening. Notably, e2d066 antibody did not select for escape mutant emergence in vitro and demonstrated neutralizing activity in vivo. Our results suggested that these antibodies may serve as prophylactic and therapeutic agents.
format Online
Article
Text
id pubmed-9499215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94992152022-09-23 Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants Yokokawa, Hiroshi Shinohara, Midori Teraoka, Yuji Imamura, Michio Nakamura, Noriko Watanabe, Noriyuki Date, Tomoko Aizaki, Hideki Iwamura, Tomokatsu Narumi, Hideki Chayama, Kazuaki Wakita, Takaji PLoS One Research Article In recent years, new direct-acting antivirals for hepatitis C virus (HCV) have been approved, but hepatitis C continues to pose a threat to human health. It is important to develop neutralizing anti-HCV antibodies to prevent medical and accidental infection, such as might occur via liver transplantation of chronic HCV patients and needle-stick accidents in the clinic. In this study, we sought to obtain anti-HCV antibodies using phage display screening. Phages displaying human hepatocellular carcinoma patient-derived antibodies were screened by 4 rounds of biopanning with genotype-1b and -2a HCV envelope E2 protein adsorbed to magnetic beads. The three antibodies obtained from this screen had reactivity against E2 proteins derived from both genotype-1b and -2a strains. However, in epitope analysis, these antibodies did not recognize linear peptides from an overlapping E2 epitope peptide library, and did not bind to denatured E2 protein. In addition, these antibodies showed cross-genotypic neutralizing activity against genotype-1a, -1b, -2a, and -3a cell culture-generated infectious HCV particles (HCVcc). Moreover, emergence of viral escape mutants was not observed after repeated rounds of passaging of HCV-infected cells in the presence of one such antibody, e2d066. Furthermore, injection of the e2d066 antibody into human hepatocyte-transplanted immunodeficient mice inhibited infection by J6/JFH-1 HCVcc. In conclusion, we identified conformational epitope-recognizing, cross-genotypic neutralizing antibodies using phage display screening. Notably, e2d066 antibody did not select for escape mutant emergence in vitro and demonstrated neutralizing activity in vivo. Our results suggested that these antibodies may serve as prophylactic and therapeutic agents. Public Library of Science 2022-09-22 /pmc/articles/PMC9499215/ /pubmed/36137152 http://dx.doi.org/10.1371/journal.pone.0274283 Text en © 2022 Yokokawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yokokawa, Hiroshi
Shinohara, Midori
Teraoka, Yuji
Imamura, Michio
Nakamura, Noriko
Watanabe, Noriyuki
Date, Tomoko
Aizaki, Hideki
Iwamura, Tomokatsu
Narumi, Hideki
Chayama, Kazuaki
Wakita, Takaji
Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants
title Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants
title_full Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants
title_fullStr Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants
title_full_unstemmed Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants
title_short Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants
title_sort patient-derived monoclonal antibody neutralizes hcv infection in vitro and vivo without generating escape mutants
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499215/
https://www.ncbi.nlm.nih.gov/pubmed/36137152
http://dx.doi.org/10.1371/journal.pone.0274283
work_keys_str_mv AT yokokawahiroshi patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT shinoharamidori patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT teraokayuji patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT imamuramichio patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT nakamuranoriko patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT watanabenoriyuki patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT datetomoko patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT aizakihideki patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT iwamuratomokatsu patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT narumihideki patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT chayamakazuaki patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants
AT wakitatakaji patientderivedmonoclonalantibodyneutralizeshcvinfectioninvitroandvivowithoutgeneratingescapemutants